Results 161 to 170 of about 4,580 (188)

Safety and efficacy of nusinersen in spinal muscular atrophy: The EMBRACE study

Muscle and Nerve, 2021
Gyula Acsádi, Perry Shieh, Diana Castro   +2 more
exaly  

Respiratory and sleep outcomes in children with SMA treated with nusinersen - real world experience

Neuromuscular Disorders, 2023
Kate Gonski, S Chuang, A Teng
exaly  

Age related treatment effect in type II Spinal Muscular Atrophy pediatric patients treated with nusinersen

Neuromuscular Disorders, 2021
Giorgia Coratti, Maria Carmela Pera, Sonia Messina   +2 more
exaly  

Nusinersen treatment of older children and adults with spinal muscular atrophy

Neuromuscular Disorders, 2021
Chamindra G Laverty, Susan Murphy, Burt Yaszay   +2 more
exaly  

Children and young adults with spinal muscular atrophy treated with nusinersen

European Journal of Paediatric Neurology, 2021
Tanja Loboda, Damjan Osredkar, Tanja Golli   +2 more
exaly  

Safety, Tolerability, and Effect of Nusinersen in Non-ambulatory Adults With Spinal Muscular Atrophy

Frontiers in Neurology, 2021
David Kline, W David Arnold, Stephen J Kolb   +2 more
exaly  

Population pharmacokinetics-based recommendations for a single delayed or missed dose of nusinersen

Neuromuscular Disorders, 2021
Michelle Farrar, Francesco Muntoni
exaly  

Nusinersen/risdiplam

Reactions Weekly, 2023
openaire   +1 more source

Circulating MyomiRs as Potential Biomarkers to Monitor Response to Nusinersen in Pediatric SMA Patients

Biomedicines, 2020
Eleonora Giagnorio, Stefania Marcuzzo, Francesca Andreetta   +2 more
exaly  

Nusinersen treatment response markers

Nature Reviews Neurology, 2022
openaire   +2 more sources